Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

New topical antiinflammatory agents and their use described by Japan Energy

Oct. 14, 2003

Recombinant alpha1-antitrypsin enters proof-of-concept study for atopic dermatitis

Oct. 13, 2003

Successful completion of phase I trial of Tbeta4

Oct. 10, 2003

Biogen licenses rights to oral psoriasis product from Fumapharm

Oct. 6, 2003

Treatment completed in phase IIb trial of MBI-594AN for acne

Oct. 6, 2003

Positive phase III results for Actiza

Oct. 2, 2003

XMP-629 enters phase I trial for topical treatment of acne

Oct. 2, 2003

Phase II trial of repifermin for chronic venous ulcers does not meet primary endpoint

Sep. 30, 2003

Cytochroma selects drug candidate for treatment of psoriasis

Sep. 26, 2003

New CCR3 antagonist with oral activity in animal model of atopic dermatitis

Sep. 25, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...